Baudax Bio Inc (BXRXQ)
Baudax Bio, Inc. is a biotechnology company listed on OTC Markets as common stock. The company has focused on developing and commercializing products for hospital and other acute care settings, with research programs that include immune-modulating therapies for orphan diseases and related complications, as well as treatments for autoimmune disorders. Its development pipeline has included BX1000, an intermediate-acting neuromuscular blocking agent in phase II testing; BX2000, an ultra-short acting neuromuscular blocking agent in phase I; a proprietary reversal agent; and BX3000, a neuromuscular blocking reversal candidate in preclinical studies. Incorporated in 2015 and based in Malvern, Pennsylvania, Baudax Bio filed a voluntary Chapter 11 reorganization petition in February 2024.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-BXRX.Q
|
—
|
—
|
—
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
0.052 K
|
—
|
—
|
—
|
—
|
—
|
—
|
